On February 11, 2026 Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, reported that Francesca Barone, M.D., Ph.D., Candel’s Chief Scientific Officer, will present data and participate in multiple sessions at the 7th Annual Glioblastoma Drug Development Summit, taking place February 17-19, 2026 in Boston, Massachusetts.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Barone will share insights from Candel’s HSV-based platform and the linoserpaturev (CAN-3110) program in recurrent high-grade glioma (rHGG) through workshop presentations and panel discussions focused on advancing biomarker-driven clinical development in glioblastoma.
Details are as follows:
Workshop Panel
Title: Harnessing Omics Data & Molecular Subtyping to Inform Patient Stratification in Clinical & Translational Strategies in Glioblastoma Drug Development
Date/Time: Tuesday, Feb. 17, 2026, 8:00 a.m. ET
Conference Presentation
Title: Integration of Biomarkers & Imaging to Define Patient Response in a Phase I/II Clinical Trial
Date/Time: Wednesday, Feb. 18, 2026, 9:30 a.m. ET
Panel Discussion
Title: Driving the Use of Biomarker-Based Enrollment in GBM Trials to Accelerate Clinical Success & Improve Patient Outcomes
Date/Time: Wednesday, Feb. 18, 2026, 12:00 p.m. ET
About linoserpaturev (CAN-3110)
CAN-3110 is a first-in-class, replication-competent, next-generation oncolytic herpes simplex virus-1 (HSV-1) immunotherapy candidate designed for dual activity for oncolysis and immune activation in a single therapeutic. In October 2023, the Company announced that Nature published results from the ongoing clinical trial where linoserpaturev was reported to be generally well tolerated with no dose-limiting toxicity. In the clinical trial, the investigators observed improved median overall survival compared to historical controls after a single linoserpaturev injection in this therapy-resistant condition.1 The Company and academic collaborators are currently supported by the Break Through Cancer foundation to evaluate the effects of repeated linoserpaturev injections in patients with recurrent glioblastoma in an expansion cohort from the phase 1b clinical trial. In October 2025, Science Translational Medicine presented findings from the comprehensive analysis of 97 serial tumor biopsies collected from two patients treated with repeated administrations of linoserpaturev in arm C. Linoserpaturev previously received Fast Track Designation and Orphan Drug Designation for the treatment of recurrent HGG from the U.S. Food and Drug Administration (FDA).
(Press release, Candel Therapeutics, FEB 11, 2026, View Source [SID1234662607])